NCT04892017 2026-04-08
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1 Terminated
Deciphera Pharmaceuticals, LLC
Eastern Cooperative Oncology Group
Pfizer
National Cancer Institute (NCI)